FGFR Inhibitor Side Effect Management

Fibroblast growth factor receptor (FGFR) inhibitors are a class of oral oncolytics approved for certain FGFR-altered malignancies, including bladder cancer (erdafitinib), cholangiocarcinoma (infigratinib and pemigatinib), and intrahepatic cholangiocarcinoma (futibatinib). FGFR inhibitors come with unique adverse effect profiles and monitoring considerations. The purpose of this PQI is to provide multidisciplinary team members with key education, monitoring, and supportive care considerations for patients on these therapies.